Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy combination platform study in advanced non-small cell lung cancer
2022-502916-35-01Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of zimberelimab, domvanalimab and quemliclustat in non-small cell lung cancer (NSCLC), sponsored by Gilead Sciences. Primary endpoints: Objective response rate and Safety and tolerability. Planned start Nov 2023; status: authorised.
02
Drugs
zimberelimabdomvanalimabquemliclustat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502916-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502916-35-01.